US biotech company Novavax acknowledged Monday it had started medical trials of its proposed Covid-19 vaccine on youngsters, in a program that may comprise as a lot as 3,000 adolescents aged 12-17.
Far fewer youngsters have been sick with Covid-19 compared with adults, and most have delicate to no indicators, nevertheless they’re usually contaminated and unfold the virus.
Novavax acknowledged the trials would check out “the efficacy (and) security” of the vaccine, with members receiving each the vaccine candidate or placebo in two doses, 21 days apart.
Members will in all probability be monitored for as a lot as two years after their injections.
The Novavax vaccine has not however been licensed in any nation, along with for adults, nevertheless the corporate plans to file for emergency authorization in Britain “within the second quarter of 2021”, adopted by inside the US.
Novavax launched on the end of January that medical trials carried out in Britain involving 15,000 adults confirmed 89.3 p.c efficacy.
The Novavax vaccine, which makes use of completely totally different know-how from the doses already broadly licensed across the globe, is a protein-based vaccine engineered from the genetic sequence of the first stress of the coronavirus.
It may very well be saved at a temperature between 2 and eight ranges Celsius (35 – 46.4 ranges Fahrenheit).
Different vaccine companies along with Moderna, Johnson & Johnson and Pfizer are moreover conducting trials in adolescents.
Europe’s medicines watchdog acknowledged Monday it had begun evaluating the utilization of Pfizer/BioNTech’s vaccine for 12- to 15-year-olds, after the identical request inside the US.
Vaccine authorization for youngsters is seen as an vital step within the route of accomplishing herd immunity.